| UniProt ID | PTBP2_HUMAN | |
|---|---|---|
| UniProt AC | Q9UKA9 | |
| Protein Name | Polypyrimidine tract-binding protein 2 | |
| Gene Name | PTBP2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 531 | |
| Subcellular Localization | Nucleus. | |
| Protein Description | RNA-binding protein which binds to intronic polypyrimidine tracts and mediates negative regulation of exons splicing. May antagonize in a tissue-specific manner the ability of NOVA1 to activate exon selection. In addition to its function in pre-mRNA splicing, plays also a role in the regulation of translation. Isoform 5 has a reduced affinity for RNA.. | |
| Protein Sequence | MDGIVTEVAVGVKRGSDELLSGSVLSSPNSNMSSMVVTANGNDSKKFKGEDKMDGAPSRVLHIRKLPGEVTETEVIALGLPFGKVTNILMLKGKNQAFLELATEEAAITMVNYYSAVTPHLRNQPIYIQYSNHKELKTDNTLNQRAQAVLQAVTAVQTANTPLSGTTVSESAVTPAQSPVLRIIIDNMYYPVTLDVLHQIFSKFGAVLKIITFTKNNQFQALLQYGDPVNAQQAKLALDGQNIYNACCTLRIDFSKLVNLNVKYNNDKSRDYTRPDLPSGDGQPALDPAIAAAFAKETSLLAVPGALSPLAIPNAAAAAAAAAAGRVGMPGVSAGGNTVLLVSNLNEEMVTPQSLFTLFGVYGDVQRVKILYNKKDSALIQMADGNQSQLAMNHLNGQKMYGKIIRVTLSKHQTVQLPREGLDDQGLTKDFGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVAEEDLRTLFANTGGTVKAFKFFQDHKMALLQMATVEEAIQALIDLHNYNLGENHHLRVSFSKSTI | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 1 | Acetylation | -------MDGIVTEV -------CCCCEEEE | 10.85 | 22814378 | |
| 16 | Phosphorylation | AVGVKRGSDELLSGS ECEEECCCCCHHCCC | 31.76 | 21406692 | |
| 16 (in isoform 3) | Phosphorylation | - | 31.76 | 21406692 | |
| 21 (in isoform 3) | Phosphorylation | - | 41.46 | 21406692 | |
| 21 | Phosphorylation | RGSDELLSGSVLSSP CCCCCHHCCCCCCCC | 41.46 | 20068231 | |
| 23 | Phosphorylation | SDELLSGSVLSSPNS CCCHHCCCCCCCCCC | 19.26 | 20068231 | |
| 26 | Phosphorylation | LLSGSVLSSPNSNMS HHCCCCCCCCCCCCC | 41.41 | 20068231 | |
| 26 (in isoform 3) | Phosphorylation | - | 41.41 | 21406692 | |
| 27 | Phosphorylation | LSGSVLSSPNSNMSS HCCCCCCCCCCCCCE | 24.76 | 20068231 | |
| 27 (in isoform 3) | Phosphorylation | - | 24.76 | 21406692 | |
| 30 | Phosphorylation | SVLSSPNSNMSSMVV CCCCCCCCCCCEEEE | 36.98 | 20068231 | |
| 33 | Phosphorylation | SSPNSNMSSMVVTAN CCCCCCCCEEEEEEC | 21.38 | 22496350 | |
| 34 | Phosphorylation | SPNSNMSSMVVTANG CCCCCCCEEEEEECC | 12.58 | 20068231 | |
| 38 | Phosphorylation | NMSSMVVTANGNDSK CCCEEEEEECCCCCC | 11.73 | 20068231 | |
| 44 | Phosphorylation | VTANGNDSKKFKGED EEECCCCCCCCCCCC | 41.57 | 20068231 | |
| 44 (in isoform 3) | Phosphorylation | - | 41.57 | 21406692 | |
| 65 | Ubiquitination | SRVLHIRKLPGEVTE CEEEEEEECCCCCCC | 59.43 | - | |
| 84 | Sumoylation | ALGLPFGKVTNILML ECCCCCCCEEEEEEE | 46.39 | - | |
| 90 | Sulfoxidation | GKVTNILMLKGKNQA CCEEEEEEECCCCHH | 3.00 | 21406390 | |
| 92 | Ubiquitination | VTNILMLKGKNQAFL EEEEEEECCCCHHHH | 54.60 | - | |
| 92 | Acetylation | VTNILMLKGKNQAFL EEEEEEECCCCHHHH | 54.60 | 26051181 | |
| 127 | Phosphorylation | HLRNQPIYIQYSNHK HHHCCCEEEEECCCC | 6.67 | 17360941 | |
| 130 | Phosphorylation | NQPIYIQYSNHKELK CCCEEEEECCCCCCC | 11.24 | 29083192 | |
| 131 | Phosphorylation | QPIYIQYSNHKELKT CCEEEEECCCCCCCC | 18.97 | 29083192 | |
| 137 | Sumoylation | YSNHKELKTDNTLNQ ECCCCCCCCCCHHHH | 55.73 | - | |
| 137 | Ubiquitination | YSNHKELKTDNTLNQ ECCCCCCCCCCHHHH | 55.73 | - | |
| 137 | Sumoylation | YSNHKELKTDNTLNQ ECCCCCCCCCCHHHH | 55.73 | - | |
| 202 | Phosphorylation | DVLHQIFSKFGAVLK HHHHHHHHHHCCEEE | 28.80 | 24719451 | |
| 215 | Sumoylation | LKIITFTKNNQFQAL EEEEEECCCCHHHHH | 50.11 | - | |
| 256 | Ubiquitination | TLRIDFSKLVNLNVK EEEECHHHHHCCCCE | 57.35 | - | |
| 269 | Phosphorylation | VKYNNDKSRDYTRPD CEECCCCCCCCCCCC | 32.99 | - | |
| 298 | Phosphorylation | AAAFAKETSLLAVPG HHHHHHCCCEEECCC | 24.78 | 27251275 | |
| 299 | Phosphorylation | AAFAKETSLLAVPGA HHHHHCCCEEECCCC | 23.60 | 27251275 | |
| 308 | Phosphorylation | LAVPGALSPLAIPNA EECCCCCCCCCCCCH | 19.82 | 28674151 | |
| 308 (in isoform 2) | Phosphorylation | - | 19.82 | 21406692 | |
| 313 (in isoform 6) | Phosphorylation | - | 20.85 | 29523821 | |
| 313 (in isoform 3) | Phosphorylation | - | 20.85 | 29523821 | |
| 313 (in isoform 4) | Phosphorylation | - | 20.85 | 29523821 | |
| 372 | Phosphorylation | VQRVKILYNKKDSAL CEEEEEEEECCCCEE | 28.54 | 20068231 | |
| 377 | Phosphorylation | ILYNKKDSALIQMAD EEEECCCCEEEEECC | 33.58 | 20068231 | |
| 388 | Phosphorylation | QMADGNQSQLAMNHL EECCCCHHHHHHHHC | 31.03 | 20068231 | |
| 401 | Phosphorylation | HLNGQKMYGKIIRVT HCCCCCCCCEEEEEE | 23.46 | 20068231 | |
| 429 | Ubiquitination | LDDQGLTKDFGNSPL CCCCCCCCCCCCCCC | 56.98 | - | |
| 434 | Phosphorylation | LTKDFGNSPLHRFKK CCCCCCCCCCCCCCC | 29.26 | 25159151 | |
| 444 | Phosphorylation | HRFKKPGSKNFQNIF CCCCCCCCCCCCCCC | 32.71 | 20068231 | |
| 473 | Phosphorylation | VAEEDLRTLFANTGG CCHHHHHHHHHHCCC | 33.26 | 30377224 | |
| 478 | Phosphorylation | LRTLFANTGGTVKAF HHHHHHHCCCCEEEE | 33.29 | 24719451 | |
| 481 | Phosphorylation | LFANTGGTVKAFKFF HHHHCCCCEEEEEHH | 21.85 | 30377224 | |
| 483 | Ubiquitination | ANTGGTVKAFKFFQD HHCCCCEEEEEHHHH | 48.20 | - | |
| 525 | Phosphorylation | ENHHLRVSFSKSTI- CCCEEEEEEECCCC- | 19.85 | 24719451 | |
| 527 | Phosphorylation | HHLRVSFSKSTI--- CEEEEEEECCCC--- | 20.42 | 26434776 | |
| 528 (in isoform 1) | Ubiquitination | - | 50.00 | 21906983 | |
| 528 | Ubiquitination | HLRVSFSKSTI---- EEEEEEECCCC---- | 50.00 | - | |
| 528 | Acetylation | HLRVSFSKSTI---- EEEEEEECCCC---- | 50.00 | 21672273 | |
| 529 (in isoform 2) | Ubiquitination | - | 30.09 | 21906983 | |
| 529 | Phosphorylation | LRVSFSKSTI----- EEEEEECCCC----- | 30.09 | 20873877 | |
| 530 | Phosphorylation | RVSFSKSTI------ EEEEECCCC------ | 34.15 | 20873877 | |
| 533 (in isoform 4) | Ubiquitination | - | 21906983 | ||
| 545 (in isoform 3) | Ubiquitination | - | 21906983 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of PTBP2_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of PTBP2_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PTBP2_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| UB2E2_HUMAN | UBE2E2 | physical | 22939629 | |
| SNRPA_HUMAN | SNRPA | physical | 22365833 | |
| PUF60_HUMAN | PUF60 | physical | 22365833 | |
| RBM10_HUMAN | RBM10 | physical | 22365833 | |
| ELAV1_HUMAN | ELAVL1 | physical | 22365833 | |
| HNRPC_HUMAN | HNRNPC | physical | 22365833 | |
| ROAA_HUMAN | HNRNPAB | physical | 22365833 | |
| RBM4_HUMAN | RBM4 | physical | 22365833 | |
| MATR3_HUMAN | MATR3 | physical | 22365833 | |
| HNRPD_HUMAN | HNRNPD | physical | 22365833 | |
| QKI_HUMAN | QKI | physical | 22365833 | |
| KHDR3_HUMAN | KHDRBS3 | physical | 22365833 | |
| KHDR1_HUMAN | KHDRBS1 | physical | 22365833 | |
| TOM1_HUMAN | TOM1 | physical | 21988832 | |
| PTBP2_HUMAN | PTBP2 | physical | 25416956 | |
| MATR3_HUMAN | MATR3 | physical | 21516116 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND MASS SPECTROMETRY. | |